MCID: VLV036
MIFTS: 46

Vulvar Disease

Categories: Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Vulvar Disease

MalaCards integrated aliases for Vulvar Disease:

Name: Vulvar Disease 11 14 75
Vulvar Diseases 43 71
Vulvar Disorders 41

Classifications:



External Ids:

Disease Ontology 11 DOID:2059
MeSH 43 D014845
NCIt 49 C27631
SNOMED-CT 68 5089007
UMLS 71 C0042994

Summaries for Vulvar Disease

MedlinePlus: 41 The vulva is the external part of a woman's genitals. Some problems you can have with the vulvar area include: Vaginitis or vulvovaginitis, swelling or infection of the vulva and vagina Skin problems due to allergy Vulvar cancer Vulvodynia, or vulvar pain Symptoms may include redness, itching, pain, or cracks in the skin. Treatment depends on the cause.

MalaCards based summary: Vulvar Disease, also known as vulvar diseases, is related to atrophic vulva and anogenital venereal wart, and has symptoms including pelvic pain and pruritus vulvae. An important gene associated with Vulvar Disease is MIR223 (MicroRNA 223), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Acetylcholine and Neurotransmitter Agents have been mentioned in the context of this disorder. Affiliated tissues include vulva, skin and lymph node, and related phenotypes are Decreased viability and neoplasm

Disease Ontology: 11 A female reproductive system disease that is located in the vulva.

Wikipedia: 75 A vulvar disease is a particular abnormal, pathological condition that affects part or all of the vulva.... more...

Related Diseases for Vulvar Disease

Diseases related to Vulvar Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 556)
# Related Disease Score Top Affiliating Genes
1 atrophic vulva 32.0 KRT7 CDKN2A
2 anogenital venereal wart 30.6 TP53 GP5 CDKN2A
3 cervix uteri carcinoma in situ 30.1 TP53 GP5 CDKN2A
4 keratosis, seborrheic 30.0 TP53 PIK3CA KRT7 CDKN2A
5 mammary paget's disease 29.9 PIP KRT7 ERBB2
6 vulval paget's disease 29.8 PIP KRT7 ERBB2 CDKN2A
7 keratosis 29.8 TP53 PIK3CA HRAS EGFR CDKN2A
8 suppressor of tumorigenicity 3 29.6 TP53 CDKN2A
9 breast disease 29.6 TP53 MIR590 MIR499A MIR223 ERBB2
10 exanthem 29.6 KIT HRAS ERBB2 EGFR CD274
11 hemangioma 29.5 TP53 PTEN KRT7 KIT EGFR CDKN2A
12 papilloma 29.4 TP53 PTEN KRT7 ERBB2 EGFR CDKN2A
13 squamous cell carcinoma 28.8 TP53 PTEN PIK3CA NRAS KRT7 HRAS
14 vulva squamous cell carcinoma 28.5 TP53 PRICKLE2-AS1 PIK3CA MIR590 MIR4712 MIR3147
15 vulva cancer 27.4 TP53 PTEN PRICKLE2-AS1 PIP PIK3CA MIR590
16 vulvitis 11.0
17 vulvar dystrophy 11.0
18 ulceration of vulva 11.0
19 cervical basaloid squamous cell carcinoma 10.4 KRT7 CDKN2A
20 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 10.4 TP53 CDKN2A
21 inverted transitional papilloma 10.4 KRT7 CDKN2A
22 endometrial transitional cell carcinoma 10.4 KRT7 CDKN2A
23 trachea carcinoma in situ 10.4 HRAS CDKN2A
24 pancreatic foamy gland adenocarcinoma 10.4 TP53 KRT7
25 tonsillar pillar cancer 10.4 EGFR CDKN2A
26 laryngeal adenoid cystic carcinoma 10.4 KRT7 KIT
27 cervical mucinous adenocarcinoma 10.4 KRT7 CDKN2A
28 vulvar sebaceous carcinoma 10.4 TP53 KRT7
29 breast hemangiopericytoma 10.4 KRT7 KIT
30 necrotizing sialometaplasia 10.4 TP53 KRT7
31 cervical adenocarcinoma 10.4 TP53 KRT7 CDKN2A
32 anal paget's disease 10.4 PIP KRT7
33 breast hemangioma 10.4 TP53 KRT7
34 childhood leptomeningeal melanoma 10.4 NRAS HRAS
35 female urethral cancer 10.4 KRT7 CDKN2A
36 nasal cavity adenocarcinoma 10.4 KRT7 HRAS
37 adenoid basal cell carcinoma 10.3 KRT7 KIT
38 bizarre leiomyoma 10.3 TP53 KIT CDKN2A
39 endometrial squamous cell carcinoma 10.3 TP53 KRT7 CDKN2A
40 melphalan allergy 10.3 NRAS CD274
41 vulvar eccrine porocarcinoma 10.3 PIP CDKN2A
42 eosinophilic variant of chromophobe renal cell carcinoma 10.3 KRT7 KIT
43 middle ear squamous cell carcinoma 10.3 GP5 CDKN2A
44 penis basal cell carcinoma 10.3 GP5 CDKN2A
45 bladder urachal carcinoma 10.3 KRT7 HRAS
46 lung adenoid cystic carcinoma 10.3 KRT7 KIT
47 neurofibrosarcoma 10.3 TP53 KIT CDKN2A
48 bladder clear cell adenocarcinoma 10.3 TP53 KRT7 CDKN2A
49 male urethral cancer 10.3 TP53 KRT7 CDKN2A
50 urachus cancer 10.3 KRT7 HRAS

Graphical network of the top 20 diseases related to Vulvar Disease:



Diseases related to Vulvar Disease

Symptoms & Phenotypes for Vulvar Disease

UMLS symptoms related to Vulvar Disease:


pelvic pain; pruritus vulvae

GenomeRNAi Phenotypes related to Vulvar Disease according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.66 EGFR HRAS PIK3CA
2 Decreased viability GR00055-A-2 9.66 EGFR HRAS PIK3CA
3 Decreased viability GR00221-A-1 9.66 CDKN2A EGFR HRAS KIT NRAS PIK3CA
4 Decreased viability GR00221-A-2 9.66 HRAS PIK3CA
5 Decreased viability GR00221-A-3 9.66 CDKN2A HRAS NRAS
6 Decreased viability GR00221-A-4 9.66 CDKN2A EGFR PIK3CA
7 Decreased viability GR00301-A 9.66 KIT
8 Decreased viability GR00402-S-2 9.66 PIK3CA

MGI Mouse Phenotypes related to Vulvar Disease:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 10.13 CDKN2A EGFR ERBB2 HRAS KIT NRAS
2 normal MP:0002873 10.11 EGFR ERBB2 GP5 HRAS KIT MIR499A
3 endocrine/exocrine gland MP:0005379 10.07 CDKN2A EGFR ERBB2 HRAS KIT NRAS
4 muscle MP:0005369 10.06 CDKN2A EGFR ERBB2 HRAS KIT MIR499A
5 no phenotypic analysis MP:0003012 10.03 CD274 CDKN2A EGFR HRAS KIT NRAS
6 cellular MP:0005384 10.03 CD274 CDKN2A EGFR ERBB2 KIT KRT7
7 digestive/alimentary MP:0005381 10.02 CDKN2A EGFR ERBB2 HRAS KIT NRAS
8 pigmentation MP:0001186 9.97 CDKN2A EGFR KIT NRAS PTEN TP53
9 respiratory system MP:0005388 9.76 CDKN2A EGFR ERBB2 HRAS KIT MIR223
10 skeleton MP:0005390 9.65 CD274 CDKN2A EGFR ERBB2 HRAS KIT
11 integument MP:0010771 9.32 CD274 CDKN2A EGFR ERBB2 HRAS KIT

Drugs & Therapeutics for Vulvar Disease

Drugs for Vulvar Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2 Neurotransmitter Agents Phase 4
3
abobotulinumtoxinA Phase 4
4 Botulinum Toxins, Type A Phase 4
5 Cholinergic Agents Phase 4
6
Nifedipine Approved Phase 3 21829-25-4 4485
7 Hormones Phase 3
8 Vasodilator Agents Phase 3
9 Calcium, Dietary Phase 3
10 calcium channel blockers Phase 3
11 Tocolytic Agents Phase 3
12
Calcium Nutraceutical Phase 3 7440-70-2 271
13
Capsaicin Approved Phase 1, Phase 2 404-86-4 1548943
14
Fludarabine Approved Phase 1, Phase 2 75607-67-9, 21679-14-1 30751 657237
15
Aldesleukin Approved Phase 1, Phase 2 110942-02-4
16
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
17 Dermatologic Agents Phase 1, Phase 2
18 Antiviral Agents Phase 1, Phase 2
19 Anti-Infective Agents Phase 1, Phase 2
20 Vaccines Phase 1, Phase 2
21 Alkylating Agents Phase 1, Phase 2
22 Antirheumatic Agents Phase 1, Phase 2
23 Anti-Retroviral Agents Phase 1, Phase 2
24 Antineoplastic Agents, Alkylating Phase 1, Phase 2
25 Anti-HIV Agents Phase 1, Phase 2
26 Immunosuppressive Agents Phase 1, Phase 2
27 Immunologic Factors Phase 1, Phase 2
28
Ropivacaine Approved Phase 1 84057-95-4 71273 175805
29
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3 3680
30
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 3003 5743
31
Methylene blue Approved, Investigational Phase 1 61-73-4 6099
32
Artesunate Approved, Investigational Phase 1 88495-63-0 6917864 5464098
33 Antiprotozoal Agents Phase 1
34 Anthelmintics Phase 1
35 Antiparasitic Agents Phase 1
36 Antimalarials Phase 1
37
Desipramine Approved, Investigational 50-47-5 2995
38
Lidocaine Approved, Vet_approved 137-58-6 3676
39
Bupivacaine Approved, Investigational 2180-92-9, 38396-39-3 2474
40
Amitriptyline Approved 50-48-6 2160
41
Baclofen Approved 1134-47-0 2284
42
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
43
Polyestradiol phosphate Approved 28014-46-2
44
Testosterone Approved, Investigational 58-22-0 5408 6013
45 Adrenergic Agents
46 Anti-Arrhythmia Agents
47 Sodium Channel Blockers
48 Psychotropic Drugs
49 Antidepressive Agents, Tricyclic
50 Antidepressive Agents

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Botox on Vulvar Vestibulitis Unknown status NCT00119886 Phase 4 Botulinum toxin
2 Topical Application of Nifedipine Cream for the Treatment of Vulvar Vestibulitis Syndrome Completed NCT00496184 Phase 3 Nifedipine cream topical application
3 Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis Completed NCT00004316 Phase 1, Phase 2 capsaicin
4 A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers Recruiting NCT02858310 Phase 1, Phase 2 Aldesleukin;Fludarabine;Cyclophosphamide
5 Evaluation of the Efficacy of Mixed Methylene Blue Compound Injection for the Treatment of Nonneoplastic Epithelial Disorders of Vulva. Completed NCT03200808 Phase 1 mixed methylene blue compound injection
6 A Phase I Proof-of-Concept Study of Artesunate Ointment for the Treatment of Patients With High-Grade Vulvar Intraepithelial Neoplasia (HSIL VIN 2/3) Active, not recruiting NCT03792516 Phase 1 artesunate ointment 40%
7 Vulvar Vestibulitis Trial: Desipramine-Lidocaine Completed NCT00276068 topical lidocaine + oral desipramine, and/or placebo
8 Effects of Flourish HEC Vaginal Care System on Reduction of Pain in Women With Localized Provoked Vulvodynia Enrolling by invitation NCT05478746
9 Open Ended Chart Review of Adult Women Presenting to the Vulvar Mucosal Specialty Clinic at Northwestern University Department of Dermatology Terminated NCT02881229
10 Treatment Prior to Injection and Biopsy of the Vulva Terminated NCT03444727

Search NIH Clinical Center for Vulvar Disease

Cochrane evidence based reviews: vulvar diseases

Genetic Tests for Vulvar Disease

Anatomical Context for Vulvar Disease

Organs/tissues related to Vulvar Disease:

FMA: Vulva
MalaCards : Skin, Lymph Node, Breast

Publications for Vulvar Disease

Articles related to Vulvar Disease:

(show top 50) (show all 224)
# Title Authors PMID Year
1
Vulvar dermatoses: a cross-sectional 5-year study. Experience in a specialized vulvar unit. 41
36089549 2022
2
Acute genital ulcers in a young girl: a clinical challenge: Lipschütz ulcer. 41
35840440 2022
3
The efficacy and safety of secondary focused ultrasound therapy for recurrence of non-neoplastic epithelial disorders of the vulva. 41
36202394 2022
4
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience. 62
34289750 2022
5
Vulvar Neoplasms (Part II). 62
35218865 2022
6
Inflammatory Vulvar Dermatoses (Part I). 62
35413374 2022
7
Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide study. 62
35483986 2022
8
Influence of Photodynamic Therapy on Lichen Sclerosus with Neoplastic Background. 62
35207373 2022
9
The Human Vulvar Microbiome: A Systematic Review. 62
34946169 2021
10
Wound complications following vulvar excision for nonmalignant lesions. 62
36277453 2021
11
The perioperative effect of anesthetic drugs on the immune response in total intravenous anesthesia in patients undergoing minimally invasive gynecological surgery. 62
35673815 2021
12
Vulvar cancer in Botswana in women with and without HIV infection: patterns of treatment and survival outcomes. 62
34493586 2021
13
Dermatographism with vulvar symptoms. 62
34621958 2021
14
Superficial lymphatic drainage of the vulva and its relation to the regional nodes: An experimental study. 62
34590298 2021
15
Fractionated Carbon Dioxide Laser for the Treatment of Vulvar Lichen Sclerosus: A Randomized Controlled Trial. 62
33957648 2021
16
Cancer-related cognitive impairment (CRCI), depression and quality of life in gynecological cancer patients: a prospective study. 62
33404703 2021
17
Four-decade trends in lymph node status of patients with vulvar squamous cell carcinoma in northern Italy. 62
33707570 2021
18
[Interdisciplinary S2k guidelines on the diagnosis and treatment of vaginal carcinoma and its precursors-recommendations on surgical pathology for histopathological workup, diagnostics, and reporting]. 62
33346872 2021
19
Diagnostic Criteria for Differentiated Vulvar Intraepithelial Neoplasia and Vulvar Aberrant Maturation. 62
33105449 2021
20
Association Between Vulvar Squamous Intraepithelial Lesions and Psychiatric Illness. 62
33181537 2021
21
Common Benign Chronic Vulvar Disorders. 62
33118795 2020
22
Clinicopathologic Diagnosis of Differentiated Vulvar Intraepithelial Neoplasia and Vulvar Aberrant Maturation. 62
32976294 2020
23
The Vulvodynia Experience Questionnaire: Qualitative Development of a New Patient-Reported Outcome Measure for Vulvodynia. 62
32900670 2020
24
Vaginal energy-based devices: characterization of adverse events based on the last decade of MAUDE safety reports. 62
33003133 2020
25
A Qualitative Exploration of Women's Experiences of Living With Chronic Vulvar Dermatoses. 62
32741746 2020
26
A randomized clinical study of the treatment of white lesions of the vulva with a fractional ultrapulsed CO2 laser. 62
32762229 2020
27
Vulvar diseases: Conditions in adults and children. 62
31712170 2020
28
Vulvar diseases: Approach to the patient. 62
31712174 2020
29
Vulvar quality of life index (VQLI) - A simple tool to measure quality of life in patients with vulvar disease. 62
31984477 2020
30
Chronic Pelvic Pain: ACOG Practice Bulletin Summary, Number 218. 62
32080045 2020
31
Chronic Pelvic Pain: ACOG Practice Bulletin, Number 218. 62
32080051 2020
32
Pediatric and Young Adult Vulvovaginal Graft-versus-Host Disease. 62
31325588 2019
33
Spironolactone May be a Cause of Hormonally Associated Vestibulodynia and Female Sexual Arousal Disorder. 62
31351850 2019
34
Basal cell carcinoma of the vulva: a case report and systematic review of the literature. 62
30506682 2019
35
No. 385-Indications for Pelvic Examination. 62
31331610 2019
36
What's New in Cosmetic Dermatology. 62
30466684 2019
37
Vulvovaginal Disease Education in Canadian and American Gynecology Residency Programs: A Survey of Program Directors. 62
29570138 2018
38
"The Future of Vulvar Disease: New and Ongoing Challenges": Presidential Lecture - XXIV World Congress 2017, Mendoza, Argentina. 62
29474239 2018
39
Diagnosis and Treatment of Vulvar Dermatoses. 62
29324620 2018
40
Generalized unprovoked vulvodynia; A retrospective study on the efficacy of treatment with amitriptyline, gabapentin or pregabalin. 62
29202395 2018
41
Role of female intimate hygiene in vulvovaginal health: Global hygiene practices and product usage. 62
28934912 2017
42
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. 62
28886907 2017
43
Evaluation and Management of Vulvar Disease. 62
28778648 2017
44
High-Yield Vulvar Histopathology for the Clinician. 62
28778634 2017
45
Fissures, Herpes Simplex Virus, and Drug Reactions: Important Erosive Vulvar Disorders. 62
28778641 2017
46
A General Approach to the Evaluation and the Management of Vulvar Disorders. 62
28778633 2017
47
Risk factors for unrecognized invasive carcinoma in patients with vulvar high-grade squamous intraepithelial lesion at vulvoscopy-directed biopsy. 62
28541626 2017
48
HPV status and favourable outcome in vulvar squamous cancer. 62
27864932 2017
49
Lichenoid vulvar disease: A review. 62
28492056 2017
50
Extra Mammary Paget's Disease of Vulva-a Case Report. 62
27872543 2016

Variations for Vulvar Disease

Expression for Vulvar Disease

Search GEO for disease gene expression data for Vulvar Disease.

Pathways for Vulvar Disease

Pathways related to Vulvar Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.86 TP53 PTEN PIP NRAS KIT HRAS
2
Show member pathways
13.83 CDKN2A EGFR ERBB2 GP5 HRAS KIT
3 13.81 CD274 EGFR ERBB2 HRAS KIT NRAS
4
Show member pathways
13.5 TP53 PTEN PIK3CA NRAS HRAS ERBB2
5
Show member pathways
13.44 EGFR ERBB2 HRAS KIT NRAS PIP
6
Show member pathways
13.41 EGFR ERBB2 HRAS KIT NRAS PIK3CA
7
Show member pathways
13.33 PTEN PIP NRAS KIT HRAS ERBB2
8
Show member pathways
13.1 TP53 PTEN PIK3CA KIT ERBB2 EGFR
9
Show member pathways
13.1 TP53 PTEN NRAS KIT HRAS EGFR
10
Show member pathways
12.97 TP53 PTEN PIK3CA NRAS KIT HRAS
11
Show member pathways
12.95 TP53 PTEN PIK3CA HRAS EGFR CDKN2A
12
Show member pathways
12.9 PTEN PIK3CA NRAS HRAS ERBB2 EGFR
13
Show member pathways
12.86 PIK3CA NRAS KIT HRAS EGFR
14 12.83 CD274 EGFR ERBB2 HRAS KIT NRAS
15
Show member pathways
12.71 PTEN PIK3CA KIT ERBB2 EGFR
16
Show member pathways
12.67 TP53 PIK3CA NRAS KIT HRAS EGFR
17 12.62 CD274 CDKN2A EGFR HRAS KIT PIK3CA
18
Show member pathways
12.61 TP53 PIK3CA NRAS HRAS ERBB2 EGFR
19
Show member pathways
12.49 TP53 PTEN PIK3CA HRAS ERBB2
20
Show member pathways
12.46 TP53 PIK3CA NRAS HRAS ERBB2 EGFR
21
Show member pathways
12.44 EGFR HRAS NRAS PIK3CA
22 12.43 TP53 NRAS HRAS EGFR
23
Show member pathways
12.43 TP53 PIK3CA NRAS HRAS ERBB2 EGFR
24
Show member pathways
12.43 TP53 PTEN PIK3CA NRAS KIT HRAS
25
Show member pathways
12.4 PIK3CA NRAS KIT HRAS ERBB2 EGFR
26
Show member pathways
12.36 EGFR ERBB2 HRAS PIK3CA
27
Show member pathways
12.35 PTEN PIK3CA NRAS HRAS
28 12.32 PTEN PIK3CA HRAS ERBB2 EGFR
29
Show member pathways
12.29 TP53 PTEN PIK3CA HRAS
30
Show member pathways
12.29 EGFR ERBB2 HRAS KIT NRAS PIK3CA
31 12.27 PIK3CA NRAS KIT HRAS EGFR
32
Show member pathways
12.26 EGFR ERBB2 HRAS NRAS PIK3CA
33
Show member pathways
12.24 PTEN NRAS HRAS EGFR
34
Show member pathways
12.19 NRAS HRAS ERBB2 EGFR
35
Show member pathways
12.16 TP53 PTEN PIK3CA HRAS CDKN2A
36
Show member pathways
12.16 TP53 PTEN PIK3CA NRAS HRAS ERBB2
37 12.14 TP53 PTEN ERBB2 EGFR
38
Show member pathways
12.14 PTEN PIK3CA HRAS ERBB2 EGFR
39
Show member pathways
12.13 PIK3CA NRAS HRAS EGFR
40
Show member pathways
12.08 PIK3CA NRAS HRAS ERBB2 EGFR
41
Show member pathways
12.06 TP53 PIK3CA ERBB2 EGFR
42
Show member pathways
12.04 PTEN PIK3CA KIT HRAS
43
Show member pathways
12.04 PIK3CA NRAS HRAS ERBB2 EGFR
44 11.98 CDKN2A HRAS PTEN TP53
45 11.96 CDKN2A EGFR HRAS KIT PIK3CA
46
Show member pathways
11.94 PIK3CA NRAS KIT HRAS
47
Show member pathways
11.93 PIK3CA NRAS HRAS EGFR
48 11.92 TP53 PTEN PIK3CA
49
Show member pathways
11.91 PIK3CA NRAS HRAS
50
Show member pathways
11.89 PIK3CA NRAS HRAS

GO Terms for Vulvar Disease

Biological processes related to Vulvar Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 10.02 MIR590 KIT HRAS EGFR CD274
2 Ras protein signal transduction GO:0007265 9.92 TP53 NRAS HRAS CDKN2A
3 phosphatidylinositol 3-kinase signaling GO:0014065 9.91 PTEN PIK3CA ERBB2
4 positive regulation of cell population proliferation GO:0008284 9.9 PTEN MIR590 MIR19B1 KIT HRAS ERBB2
5 positive regulation of MAP kinase activity GO:0043406 9.86 EGFR ERBB2 HRAS KIT
6 positive regulation of gene expression GO:0010628 9.61 TP53 PIP MIR223 KIT HRAS ERBB2
7 negative regulation of immature T cell proliferation in thymus GO:0033088 9.58 ERBB2 CDKN2A
8 positive regulation of miRNA maturation GO:1903800 9.46 TP53 EGFR
9 regulation of cell population proliferation GO:0042127 9.17 TP53 KIT HRAS ERBB2 EGFR

Molecular functions related to Vulvar Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA base-pairing translational repressor activity GO:1903231 8.92 MIR590 MIR499A MIR223 MIR19B1

Sources for Vulvar Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....